Physician profile
Charles D Evans
NPI 1982655643
$4,528.14
in general payments reported to CMS, 2019-2025
22 companies · $606 in 2025
The $606 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $124 · 2021: $603 · 2022: $970 · 2023: $694 · 2024: $745 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,367.98 | 2022-2025 | |
| Alcon Vision LLC | $894.04 | 2019-2025 | Hydrus Microstent, Tryptyr, Eysuvis |
| Bausch & Lomb Americas INC. | $320.34 | 2022-2025 | Vyzulta, Envista Mx60 Iol, Miebo |
| Glaukos Corporation | $277.12 | 2019-2024 | Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $260.67 | 2019-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $233.26 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $208.46 | 2019-2021 | |
| Oyster Point Pharma, INC. | $143.38 | 2022-2025 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $131.89 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $123.81 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $107.15 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $72.62 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $69.70 | 2019-2020 | |
| Dompe US, INC. | $69.36 | 2023-2024 | Oxervate |
| Ivantis, INC | $53.07 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $43.79 | 2022-2023 | Eylea |
| Amgen INC. | $40.38 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $31.90 | 2021-2022 | |
| Horizon Therapeutics Plc | $22.69 | 2023 | Tepezza |
| Shire North American Group INC | $21.82 | 2019 | |
| Ocular Therapeutix, INC. | $20.31 | 2023 | Dextenza |
| Biotissue Holdings INC. | $14.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.